DrugPatentWatch Database Preview

Eisai Inc Company Profile

EISAI INC has sixteen approved drugs.

There are thirty-two US patents protecting EISAI INC drugs.

There are six hundred and ninety-one patent family members on EISAI INC drugs in fifty-five countries and sixty supplementary protection certificates in seventeen countries.

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eisai Inc	LENVIMA	lenvatinib mesylate	CAPSULE;ORAL	206947-001	Feb 13, 2015		RX	Yes	No		Start Trial				Start Trial
Eisai Inc	BELVIQ XR	lorcaserin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208524-001	Jul 15, 2016		DISCN	Yes	No	8,946,207	Start Trial	Y			Start Trial
Eisai Inc	FYCOMPA	perampanel	SUSPENSION;ORAL	208277-001	Apr 29, 2016		RX	Yes	Yes	8,772,497	Start Trial		Y		Start Trial
Eisai Inc	LENVIMA	lenvatinib mesylate	CAPSULE;ORAL	206947-002	Feb 13, 2015		RX	Yes	Yes		Start Trial				Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Eisai Inc	ARICEPT	donepezil hydrochloride	TABLET;ORAL	020690-002	Nov 25, 1996	6,372,760	Start Trial
Eisai Inc	BANZEL	rufinamide	SUSPENSION;ORAL	201367-001	Mar 3, 2011	7,750,028*PED	Start Trial
Eisai Inc	ARICEPT	donepezil hydrochloride	TABLET;ORAL	020690-002	Nov 25, 1996	4,895,841	Start Trial
Eisai Inc	HALAVEN	eribulin mesylate	SOLUTION;INTRAVENOUS	201532-001	Nov 15, 2010	6,469,182	Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	23 mg	➤ Subscribe	2013-07-09
➤ Subscribe	Oral Suspension	40 mg/mL	➤ Subscribe	2014-06-16
➤ Subscribe	Extended-release Tablets	20 mg	➤ Subscribe	2016-12-13
➤ Subscribe	Tablets	10 mg	➤ Subscribe	2016-06-27
➤ Subscribe	Capsules	4 mg and 10 mg	➤ Subscribe	2019-02-13
➤ Subscribe	Tablets	100 mg, 200 mg and 400 mg	➤ Subscribe	2012-11-14
➤ Subscribe	Tablets	2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg	➤ Subscribe	2016-10-24
➤ Subscribe	Orally Disintegrating Tablets	5 mg and 10 mg	➤ Subscribe	2010-06-30

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1087960	C01087960/01	Switzerland	Start Trial	PRODUCT NAME: ERIBULIN; REGISTRATION NO/DATE: SWISSMEDIC 59489 20110513
1415987	92858	Luxembourg	Start Trial	PRODUCT NAME: LENVATINIB, OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES OU UN HYDRATE DE CELUI-CI
1300396	2013C/003	Belgium	Start Trial	PRODUCT NAME: FYCOMPA-PERAMPANEL; AUTHORISATION NUMBER AND DATE: EU/1/12/776/001 20120723
1415987	132016000024218	Italy	Start Trial	PRODUCT NAME: LENVATINIB O UN SUO SALE ACCETTABILE FARMACEUTICAMENTE O SUO IDRATO(LENVIMA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/1002/001-002, 20150601
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.